When used in conjunction with oncolytic virotherapy for the treatment of breast and other metastatic cancers, KISS1 transgenic expression has the potential to be an efficient tool for CRAd-mediated cytotoxicity in BC cells [159]. The gene discussed is KISS1; the disease is breast cancer.